Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 2/20 | 0.59 |
| ▸ | WHR1 | P49842 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260544 | 0.88 | MAOA (0.53) | MAOAMAOBNQO2WHR1PDPK1 | |
| SCHEMBL9601982 | 0.88 | NQO2 (0.52) | NQO2WHR1POLBLMNASMN1; SMN2 | |
| SCHEMBL19260709 | 0.83 | EGFR (0.49) | PDPK1KDM4ETDP1EHMT2 | |
| SCHEMBL9594949 | 0.82 | KDM4E (0.49) | NQO2POLBLMNASMN1; SMN2KDM4E | |
| SCHEMBL9595219 | 0.82 | TP53 (0.46) | NQO2WHR1POLBSMN1; SMN2KDM4E | |
| SCHEMBL9594408 | 0.82 | KDM4E (0.51) | NQO2POLBLMNASMN1; SMN2KDM4E | |
| SCHEMBL9594424 | 0.82 | LMNA (0.47) | NQO2WHR1POLBLMNASMN1; SMN2 | |
| SCHEMBL15124839 | 0.82 | MAOA (0.82) | MAOAMAOBNQO2POLBLMNA | |
| SCHEMBL20734756 | 0.82 | EGFR (0.50) | POLBSMN1; SMN2KDM4EALOX15EHMT2 | |
| SCHEMBL6023624 | 0.80 | KDM4E (0.61) | MAOAMAOBNQO2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668863-B1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-111372927-A | Tricyclic compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-3936457-A | VASODILATION | WARNER-LAMBERT COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | MAOA 3265/4885MAOB 3310/4885NQO2 619/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | MAOA 3265/4885MAOB 3310/4885NQO2 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.